March 5, 2020 / 12:33 PM / a month ago

BRIEF-Actinium Pharmaceuticals Announces First Patient Treated In Third And Final Dose Cohort Of Actimab-A Clag-M Combination Phase 1 Trial In Acute Myeloid Leukemia

March 5 (Reuters) - Actinium Pharmaceuticals Inc:

* ACTINIUM PHARMACEUTICALS ANNOUNCES FIRST PATIENT TREATED IN THIRD AND FINAL DOSE COHORT OF ACTIMAB-A CLAG-M COMBINATION PHASE 1 TRIAL IN ACUTE MYELOID LEUKEMIA

* ACTINIUM PHARMACEUTICALS INC - ACTINIUM EXPECTS THIRD COHORT TO BE COMPLETED MID-2020. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below